Clinical Trials Browser

Phase 3 × Mesothelioma, Malignant × tumor necrosis factor-alpha, CNGRC fusion protein, human × Clear all

NCT01098266 2019-09-17

NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

Phase 3 Completed

400 enrolled 16 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant